

Ausgaben der ÖGK für Antidiabetika

	2016	2017	2018	2019	2020	2021	2022	2023
A10 - Antidiabetika gesamt	€ 116.922.433,15	€ 129.771.542,65	€ 140.557.233,85	€ 154.123.146,10	€ 170.955.186,25	€ 182.325.860,85	€ 200.902.638,30	€ 218.336.814,85
A10A - INSULINE UND ANALOGA	€ 40.951.962,25	€ 41.532.048,50	€ 41.741.240,75	€ 42.294.621,45	€ 43.969.589,80	€ 43.041.127,75	€ 42.318.886,25	€ 41.234.636,55
A10B - ANTIDIABETIKA, EXKL. INSULINE	€ 75.970.470,90	€ 88.239.494,15	€ 98.815.993,10	€ 111.828.524,65	€ 126.985.596,45	€ 139.284.733,10	€ 158.583.752,05	€ 177.102.178,30
A10BA Biguanide	€ 5.078.078,65	€ 4.192.309,55	€ 2.737.461,95	€ 2.759.580,70	€ 2.785.539,55	€ 2.319.301,70	€ 2.388.053,65	€ 2.347.860,25
A10BB Sulfonylharnstoffe	€ 3.216.378,35	€ 2.859.551,85	€ 2.518.976,60	€ 2.225.029,45	€ 1.948.280,20	€ 1.765.049,45	€ 1.618.430,75	€ 1.394.370,00
A10BD Kombinationen von oralen Antidiabetika	€ 37.959.278,75	€ 43.353.208,10	€ 48.453.738,40	€ 53.057.178,20	€ 58.334.712,50	€ 60.945.749,00	€ 63.251.330,95	€ 59.556.360,70
A10BF Alpha-Glukosidasehemmer	€ 249.729,70	€ 208.927,50	€ 174.055,60	€ 109.160,30	€ 1.789,55	€ 23,95	€ 0,00	€ 0,00
A10BG Thiazolidindione	€ 1.456.484,15	€ 1.322.967,10	€ 1.161.081,70	€ 1.111.505,60	€ 1.148.158,50	€ 1.160.547,45	€ 1.144.616,80	€ 1.088.390,55
A10BH Dipeptidyl-Peptidase 4-Inhibitoren	€ 16.658.447,40	€ 19.005.363,95	€ 20.580.929,50	€ 22.138.654,10	€ 23.483.698,55	€ 23.901.341,40	€ 23.589.308,20	€ 21.144.475,25
A10BJ GLP-1-Analoga	€ 2.639.808,20	€ 6.103.717,65	€ 8.394.924,20	€ 12.547.315,35	€ 17.870.515,10	€ 23.667.279,05	€ 30.302.767,15	€ 36.785.998,95
A10BK SGLT-2-Inhibitoren	€ 3.743.456,65	€ 10.976.084,45	€ 14.633.080,90	€ 17.739.017,60	€ 21.286.561,40	€ 25.412.243,30	€ 36.194.703,05	€ 54.707.718,90
A10BX Andere Antidiabetika, exkl. Insuline	€ 4.968.809,05	€ 217.364,00	€ 161.744,25	€ 141.083,35	€ 126.341,10	€ 113.197,80	€ 94.541,50	€ 77.003,70

Datenquelle: BIG - zeitliche Entwicklung

VM2 - Dr.Fi, 25.07.2024

